Anika Therapeutics, Inc.
ANIK· Nasdaq
ANIKAnika Therapeutics, Inc.
Released Feb 26, 2026, before the open
10-K filed Mar 3, 2026, 62 days after period end · 0001171843-26-001275
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $30.62M | $30.60M | — | — |
| Net Income | $292.00K |
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
| -$21.87M |
| -$63.00M |
| -$4.91M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
